Biocon Q1 FY25 Results: Biocon, a leading biopharmaceutical company, is set to announce its first-quarter financial results for the fiscal year 2024 tomorrow, August 8, 2024. The results will provide valuable insights into the company’s performance and financial health for the period ending June 30, 2024. The exact timings of the results are not known.

To stay informed about Biocon’s Q1 results, you can access the live webcast of the announcement on the company’s official website. Visit the Investor Relations section of Biocon’s website, where a link to the webcast will be provided. Access it here: https://www.biocon.com/investor-relations/

Also Read

The webcast will offer real-time updates and detailed information regarding Biocon’s financial performance, including key metrics such as revenue, net profit, and operational highlights.

The Q1 FY25 earnings call will be held on Friday, August 9, at 9 AM. You can register at this link: https://biocon.zoom.us/webinar/register/WN_iwHAQp9wQqmwLpuaiqZMsg#/

In addition to the live webcast, financial news channels and major business news platforms, including financialexpress.com, will also cover the results and offer expert analysis. For those interested in detailed financial documents, Biocon will upload the results and related reports to its website shortly after the announcement. These documents will be available in the ‘Investor Relations’ or ‘Financial Reports’ section.

As of Wednesday, August 7, 2024, Biocon shares are trading at Rs 347 on the Bombay Stock Exchange (BSE) at 3:29 PM and Rs 346.85 on the National Stock Exchange (NSE) at 3:54 PM. The market cap of Biocon stands at Rs 4,16,428 million.

Biocon’s Q1 results are closely watched by investors, analysts, and industry experts due to the company’s significant role in the biopharmaceutical sector. The results will shed light on how well the company has navigated market challenges and growth opportunities in the first quarter of the fiscal year.

The results for Biocon’s Q1 results for FY24 will also be published on both the Bombay Stock Exchange (BSE) and National Stock Exchange (NSE) websites.

Biocon last quarter performance

Biocon reported a 57% decline in consolidated net profit to Rs 136 crore for Q4 of FY24, down from Rs 313 crore a year earlier, primarily due to higher expenses. Total revenue for the quarter increased slightly to Rs 3,966 crore from Rs 3,929 crore. For the full year, total revenue surged to Rs 15,621 crore from Rs 11,550 crore. Biocon reported a revenue of Rs 15,621 crore, marking a 35% increase. EBITDA rose by 44% to Rs 4,164 crore. Net profit before exceptional items reached Rs 1,030 crore, up 31%. Notably, biosimilars revenue surpassed USD 1 billion.